DE602005007494D1 - Azaindolinhibitoren von mtp und apob - Google Patents

Azaindolinhibitoren von mtp und apob

Info

Publication number
DE602005007494D1
DE602005007494D1 DE602005007494T DE602005007494T DE602005007494D1 DE 602005007494 D1 DE602005007494 D1 DE 602005007494D1 DE 602005007494 T DE602005007494 T DE 602005007494T DE 602005007494 T DE602005007494 T DE 602005007494T DE 602005007494 D1 DE602005007494 D1 DE 602005007494D1
Authority
DE
Germany
Prior art keywords
azaindolinhibitors
apob
mtp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005007494T
Other languages
English (en)
Inventor
Alyx Caroline Guevel
Catherine Vidal
Bruno Roux
Olivier Chevreuil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE602005007494D1 publication Critical patent/DE602005007494D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005007494T 2004-07-27 2005-06-28 Azaindolinhibitoren von mtp und apob Active DE602005007494D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408302A FR2873694B1 (fr) 2004-07-27 2004-07-27 Nouveaux aza-indoles inhibiteurs de la mtp et apob
PCT/EP2005/006930 WO2006010423A2 (en) 2004-07-27 2005-06-28 Azaindole inhibitors of mtp and apob

Publications (1)

Publication Number Publication Date
DE602005007494D1 true DE602005007494D1 (de) 2008-07-24

Family

ID=34948943

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005007494T Active DE602005007494D1 (de) 2004-07-27 2005-06-28 Azaindolinhibitoren von mtp und apob

Country Status (16)

Country Link
US (1) US7838533B2 (de)
EP (1) EP1771446B1 (de)
JP (1) JP5161569B2 (de)
AR (1) AR050436A1 (de)
AT (1) ATE398126T1 (de)
AU (1) AU2005266662B2 (de)
CA (1) CA2575223C (de)
CY (1) CY1108306T1 (de)
DE (1) DE602005007494D1 (de)
DK (1) DK1771446T3 (de)
ES (1) ES2308510T3 (de)
FR (1) FR2873694B1 (de)
PL (1) PL1771446T3 (de)
PT (1) PT1771446E (de)
SI (1) SI1771446T1 (de)
WO (1) WO2006010423A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
PL2666859T3 (pl) 2006-04-03 2019-09-30 Roche Innovation Center Copenhagen A/S Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2126079A1 (de) 2007-03-22 2009-12-02 Santaris Pharma A/S Rna-antagonistenverbindungen zur hemmung der apo-b100-expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP6035010B2 (ja) 2007-10-04 2016-11-30 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ マイクロｍｉｒ
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2268811A1 (de) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2739144A4 (de) * 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc Verbindungen und ihre therapeutische verwendung
EP3591054A1 (de) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Gegen pcsk9 gerichtete antisense-oligomere und konjugate
CN113874015B (zh) 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
BR0210616A (pt) * 2001-06-28 2004-09-28 Pfizer Prod Inc Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
CA2486933A1 (en) * 2002-05-31 2003-12-11 Yamanouchi Pharmaceutical Co., Ltd. Tetrahydropyran derivative
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
JP4737495B2 (ja) * 2004-01-14 2011-08-03 塩野義製薬株式会社 エリスロマイシン誘導体

Also Published As

Publication number Publication date
ATE398126T1 (de) 2008-07-15
AU2005266662A1 (en) 2006-02-02
FR2873694B1 (fr) 2006-12-08
CY1108306T1 (el) 2014-02-12
WO2006010423A3 (en) 2006-03-02
FR2873694A1 (fr) 2006-02-03
US20090036481A1 (en) 2009-02-05
US7838533B2 (en) 2010-11-23
PL1771446T3 (pl) 2008-10-31
PT1771446E (pt) 2008-09-17
SI1771446T1 (sl) 2008-10-31
JP5161569B2 (ja) 2013-03-13
WO2006010423A2 (en) 2006-02-02
JP2008508198A (ja) 2008-03-21
EP1771446B1 (de) 2008-06-11
ES2308510T3 (es) 2008-12-01
AU2005266662B2 (en) 2011-04-21
CA2575223A1 (en) 2006-02-02
CA2575223C (en) 2013-08-06
AR050436A1 (es) 2006-10-25
EP1771446A2 (de) 2007-04-11
DK1771446T3 (da) 2008-09-22

Similar Documents

Publication Publication Date Title
DE602005007494D1 (de) Azaindolinhibitoren von mtp und apob
DE602005011285D1 (de) Formmasse von polymer
DE602005012267D1 (de) N von geräten
DE602005017635D1 (de) Harzzusammensetzung und formteil daraus
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE486091T1 (de) Vegf-fallen und therapeutische verwendungen dafür
DE602005022220D1 (de) Uhrwerk und display
DE602006020061D1 (de) Mucin-glycoprotein und anwendung davon
ATE391718T1 (de) Phenylacetamide und ihre verwendung als glukokinase-modulatoren
DE602006007831D1 (de) N-alkylcarbonylaminosäureester und n-alkylcarbonylaminosäurelaktonverbindungen und anwendung davon
DE602005003819D1 (de) Perfluoroelastomer- und fluoroplastikgemische
DE602005007987D1 (de) achtelung und -entschachtelung
DE602006018166D1 (de) Polyrotaxanhaltige lösung und verwendung davon
ATE523594T1 (de) Modifizierung von pflanzenentwicklung und - morphologie
DE502005006286D1 (de) Verwendung von trisubstituierten benzopyranonen
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
FI20030261A (fi) Iskulaite
DE602005009321D1 (de) Hinonen und 3-o-geschützten morphinondienolcarboxylaten
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
DE602005012674D1 (de) Nachweiselement und nachweisverfahren
DE602006006710D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
ATE499096T1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
DE602004015504D1 (de) Von injektionspräparaten
DE602005001066D1 (de) Komplexe Emulsionen von Perfluoropolyethern
ATE409477T1 (de) Kombination von voriconazol und einem antifungalen cyp2c19-inhibitor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition